ClinicalTrials.gg

Program

SHR-1905

A development code. Also written as “SHR-1905 Injection”.

In Jiangsu HengRui Medicine's pipeline, TSLP. Its studies are mostly in Asthma · Nasal Polyps · Dermatitis, Atopic, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Jul 25, 20257 company-led studies, 3 open or runningNext primary completion: Jan 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine73 open or runningphase 3since Jul 25, 2025Mar 11, 2021Jan 2028phase 3 · NCT07098403
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-1905, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2021First study: phase 1 study in AsthmaFirst studyNCT04800263 · 50 enrolled · Australia
  2. Oct 14, 2022Phase 2 study in AsthmaNCT05593250 · 260 enrolled · China
  3. May 25, 2023Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT05891483 · 114 enrolled · China
  4. Jan 9, 2025Phase 2 study in Adolescent AsthmaNCT06786455 · 9 enrolled · China
  5. Jul 25, 2025Phase 3 study in AsthmaNCT07098403 · 408 planned · China
  6. Aug 13, 2025Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07132827 · 280 planned · China
  7. Sep 30, 2025Phase 2 study in Moderate-to-severe Atopic DermatitisNCT07211542 · 75 planned · China

Ahead

  1. Jan 2028Primary completion: phase 3 study in AsthmaNCT07098403
  2. Apr 2028Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT07132827

TargetBeta

“TSLP”the company's pipeline, read by Claude · source

Other programs on TSLP

ProgramCompanyFurthest phaseStudies
tezepelumabruleAstraZenecaphase 434
tilrekimigPfizerphase 311
lunsekimigSanofiphase 310
felcorekibartGlaxoSmithKlinephase 39
TQC2731Sino Biopharmaceuticalphase 37
WIN378rulewindward-biophase 22
CDX-622ruleCelldex Therapeuticsphase 12
HXN-1013ruleHelixon Biotechnology (Suzhou)phase 11
HY6725ruleNewsoara Biopharmaphase 11

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07211542Moderate-to-severe Atopic Dermatitis · China2RecruitingSep 202675
NCT07132827Chronic Rhinosinusitis With Nasal Polyps · China3RecruitingApr 2028280
NCT07098403Asthma · China3RecruitingJan 2028408
NCT06786455Adolescent Asthma · China2CompletedDec 3, 20259
NCT05891483Chronic Rhinosinusitis With Nasal Polyps · China2CompletedJan 21, 2026114
NCT05593250Asthma · China2CompletedDec 5, 2025260
NCT04800263Asthma · Australia1CompletedNov 12, 202250

How it is read

Names in the registry

  • “SHR-1905 Injection”, 5 entries
  • “SHR-1905”, 2 entries

Codes read as this program: SHR1905.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.